Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.65 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.61 |
| ▸ | RET | P07949 | 3/20 | 0.61 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 4/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.57 |
| ▸ | FLT1 | P17948 | 1/20 | 0.57 |
| ▸ | CDK2 | P24941 | 1/20 | 0.57 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.57 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.57 |
| ▸ | KIF5B | P33176 | 1/20 | 0.57 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 2/20 | 0.56 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5485308 | 0.88 | EGFR (0.77) | EGFRMAPK14RETABCG2SRC | |
| Hydrochloric Acid SCHEMBL5471735 | 0.87 | EGFR (0.75) | EGFRMAPK14RETABCG2SRC | |
| SCHEMBL3238360 | 0.87 | KDR (0.74) | EGFRMAPK14LRRK2RETABCG2 | |
| SCHEMBL3531488 | 0.85 | AURKB (0.80) | EGFRMAPK14KDRAURKAAURKB | |
| SCHEMBL3238919 | 0.84 | EGFR (0.70) | EGFRMAPK14RETABCG2SRC | |
| Hydrochloric Acid SCHEMBL3238911 | 0.83 | EGFR (0.68) | EGFRMAPK14RETABCG2SRC | |
| SCHEMBL3239025 | 0.81 | EGFR (0.66) | EGFRMAPK14RETABCG2SRC | |
| SCHEMBL17940152 | 0.81 | EGFR (0.70) | EGFRMAPK14RETABCG2SRC | |
| SCHEMBL3240732 | 0.80 | EGFR (0.77) | EGFRKDRAURKAAURKB | |
| SCHEMBL3238867 | 0.80 | EGFR (0.77) | EGFRKDRAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1369418-B1 | QUINAZOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-20070265260-A1 | Quinazoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20070265260-A1 | Quinazoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20070265260-A1 | Quinazoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| US-7294629-B2 | Quinazoline derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-13 | — | — | US | disclosed |
| US-7294629-B2 | Quinazoline derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-13 | — | — | US | disclosed |
| US-7294629-B2 | Quinazoline derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-13 | — | — | US | disclosed |
| US-20040116422-A1 | Quinazoline derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1369418-A1 | QUINAZOLINE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2003-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265260-A1 | Quinazoline derivatives | TYK2, ROR1, JAK1 | EGFR 1535/4885MAPK14 47/4885LRRK2 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.